BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VASAMED (OPSI) Receives CE Mark For AcQtrac(TM) System


1/4/2006 1:33:30 PM

MINNEAPOLIS, Jan. 4 /PRNewswire-FirstCall/ -- VASAMED , a leader in noninvasive, hemodynamic assessment technology, announced that it received CE Mark for its new AcQtrac(TM) System. The AcQtrac System provides real-time measurements of hemodynamic parameters that allow physicians to more effectively manage a broad range of cardiovascular patients.

"Each year, cardiovascular disease contributes to nearly half of all deaths in Europe and the European Union, which represents approximately 6 million people. Overall, heart disease is estimated to cost Europe euro 169 billion annually," said Paulita LaPlante, president and CEO of VASAMED. "The AcQtrac System's rapid, noninvasive cardiovascular assessment can be a cost-effective alternative for a market focused on earlier diagnosis and treatment as part of their overall health policy objectives."

Also cleared for use in the United States by the FDA earlier this year, the AcQtrac System is the next generation in noninvasive cardiovascular assessment that provides accurate, repeatable and reliable cardiac and circulatory health information. It relies on a unique graphical waveform that represents the mechanical function of the cardiovascular system and provides vital information to quickly assess conditions such as congestive heart failure or to monitor treatment outcomes such as those provided by drug therapy.

"The AcQtrac(TM) ICG impedance cardiograph has provided us an invaluable tool in the management of congestive heart failure in a clinical setting," said James Leibsohn, MD, an interventional cardiologist at St. Luke's Medical Center, Milwaukee, Wisconsin. "We are now able to accurately determine peripheral resistance and cardiac output in an outpatient setting and, for the first time, adjust medications precisely on the basis of accurate hemodynamic measurements."

In addition to the AcQtrac System, VASAMED manufactures the SensiLase(TM) PAD 3000 and LASERDOPP(TM) PV2000 System for quantitative evaluation of microcirculatory perfusion in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Laser Doppler technology, coupled with proprietary algorithms to measure skin perfusion pressure and pulse volume, assist physicians in evaluating microvascular health and improving blood flow and wound healing in their patients. The accuracy of the skin perfusion pressure measurement is not affected by edema, anemia, medial calcification or certain other conditions that limit the usefulness of other measurement technologies. VASAMED has also developed a system for the measurement of sublingual CO2, which can be used in a variety of hemodynamic diagnostic applications.

For more information about VASAMED, visit http://www.vasamed.com .

VASAMED

CONTACT: Wes Peterson, CFO of VASAMED, +1-952-944-5857 ext. 542



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES